Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amyotrophic lateral sclerosis: sonographic evaluation of dysphagia.
Tamburrini S, Solazzo A, Sagnelli A, Del Vecchio L, Reginelli A, Monsorrò M, Grassi R. Tamburrini S, et al. Among authors: solazzo a. Radiol Med. 2010 Aug;115(5):784-93. doi: 10.1007/s11547-010-0523-2. Epub 2010 Feb 19. Radiol Med. 2010. PMID: 20174881 English, Italian.
Earliest videofluoromanometric pharyngeal signs of dysphagia in ALS patients.
Solazzo A, Monaco L, Vecchio LD, Reginelli A, Iacobellis F, Capasso R, Tamburrini S, Berritto D, Barillari MR, Monsurrò MR, Di Martino N, Grassi R. Solazzo A, et al. Dysphagia. 2014 Oct;29(5):539-44. doi: 10.1007/s00455-014-9542-9. Epub 2014 Aug 21. Dysphagia. 2014. PMID: 25142240
Breast Cancer Adjuvant Radiotherapy in Up-Front to Chemotherapy: Is There a Worthwhile Benefit? A Preliminary Report.
Lazzari G, Benevento I, Montagna A, D'Andrea B, De Marco G, Castaldo G, Bianculli A, Tucciariello R, Metallo V, Solazzo AP. Lazzari G, et al. Among authors: solazzo ap. Breast Cancer (Dove Med Press). 2024 Jul 15;16:359-367. doi: 10.2147/BCTT.S471345. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39050764 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
45 results